Semaglutide as a promising anti-obesity drug

​

Semaglutide is a GLP-1 RA (Glucagon-Like Peptide-1 Receptor Agonist) which is administered subcutaneously once per week. It is produced by the same manufacturer as Liraglutide (Novo Nordisk).

 

During a Phase II dose-finding trial, the weight loss efficacy of Semaglutide appeared to be superior compared to Liraglutide & the placebo doses for those who were obese but without Type 2 Diabetes.

​

Read the full article below.